Momelotinib

13 interactions 1 explained in plain English
Also sold as: Ojjaara
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Simvastatin Alpelisib Cyclosporine Injection Cyclosporine Ophthalmic Darolutamide Gemfibrozil
11 Major 2 Moderate
All (13) Major (11) Moderate (2)

Major

Momelotinib Simvastatin Flolipid Explained Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Momelotinib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Momelotinib Cyclosporine Injection Atopica Increased momelotinib exposure and an increased risk of momelotinib-related adverse reactions Details Momelotinib Cyclosporine Ophthalmic Cequa Increased momelotinib exposure and an increased risk of momelotinib-related adverse reactions Details Momelotinib Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Momelotinib Gemfibrozil Lopid Increased momelotinib exposure and an increased risk of momelotinib-related adverse reactions Details Momelotinib Irinotecan Camptosar Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Momelotinib Irinotecan Injection Camptosar Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Momelotinib Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Momelotinib Methotrexate Jylamvo Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Momelotinib Methotrexate Injection Abitrexate® Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details

Moderate

Momelotinib Encorafenib Braftovi Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Momelotinib Levothyroxine Ermeza Increased risk of hypothyroidism Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.